Pradaxa (dabigatran etexilate) is a small molecule pharmaceutical. Dabigatran etexilate was first approved as Pradaxa on 2008-03-17. It is used to treat pulmonary embolism in the USA. It has been approved in Europe to treat replacement arthroplasty and venous thromboembolism. It is known to target prothrombin. Pradaxa's patents are valid until 2031-01-20 (FDA).
|Common Name||Dabigatran etexilate|
|Indication||pulmonary embolism, replacement arthroplasty, venous thromboembolism|
|Drug Class||Thrombin inhibitors (argatroban type)|